Preparation of organic-modified magadiite–magnetic nanocomposite particles as an effective nanohybrid drug carrier material for cancer treatment and its properties of sustained release mechanism by Korsmeyer–Peppas kinetic model

• Published in: Journal of materials science Vol. 56; no. 25; pp. 14270 - 14286
• Main Authors: Ge, Mingliang, Li, Yueying, Zhu, Caiping, Liang, Guodong, S.M., Jahangir Alam, Hu, Guoqing, Gui, Yuee, M., Junaebur Rashid
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.09.2021; Springer; Springer Nature B.V
• Subjects: Analysis; Buffers; Cancer therapies; Cetyltrimethylammonium bromide; Characterization and Evaluation of Materials; Chemistry and Materials Science; Classical Mechanics; Crystallography and Scattering Methods; Drug carriers; Drug delivery systems; Drugs; Fluorouracil; Health aspects; Iron oxides; Materials for Life Sciences; Materials Science; Nanocomposites; Nanoparticles; Particulate composites; Polymer Sciences; Solid Mechanics; Sustained release; Vehicles
• ISSN: 0022-2461; 1573-4803
• DOI: 10.1007/s10853-021-06181-w

Cancer is a major threat to human health, and the morbidity is increasing these years for cancer disease; we emphasized to put forward higher requirements for the development of novel pharmaceutic preparations of organic-modified magadiite–magnetic nanocomposite particles as an effective nanohybrid drug carrier material for cancer treatment with high efficiency, sustained releasing and targeted delivery properties. Herein, the nanoparticles Fe 3 O 4 were supported on cetyltrimethyl ammonium-bromide (CTAB)-modified magadiite (CTAB-MAG) by coprecipitation method to prepare magnetic composite particles (CTAB-MAG–Fe 3 O 4 ). Compared with the existing drug carriers, the obtained CTAB-MAG–Fe 3 O 4 exhibited high drug loading capacity up to 123.98 mg/g of binding anticancer drug 5-fluorouracil (5-FU), whereas the drug accumulated release ratio was found 55.94% after 48 h. The sustained releasing properties showed that the drug loading and the drug utilization rate of CTAB-MAG–Fe 3 O 4 were significantly improved in the simulated gastric fluid buffer and the simulated intestinal fluid buffer. Therefore, orally taking 1.21–2.41 g of CTAB-MAG–Fe 3 O 4 /5-FU could satisfy the patients’ demand once-per-day. According to sustained releasing kinetics research, the sustained releasing process was conformed to the Korsmeyer–Peppas kinetic model, which was mainly controlled by diffusion process and it belonged to Fickian diffusion model. The prepared drug carrier system combined the advantages of the iron oxide nanoparticles with layered silicate MAG, which will be potential in applications of drug delivery system. Graphical abstract